Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout

A couple of complex collaboration agreements that Bristol Myers Squibb (NYSE:BMY) inherited from Celgene are about to get a lot simpler. The big pharma is going to buy out its obligations to bluebird bio (NASDAQ:BLUE) in all territories outside of the U.S. for just $200 million.